The treatment of cancer by raising its temperature to 40-45°C for periods of minutes to hours is exciting considerable current interest. Experimental clinical work has resulted in a large body of new information with several scientific meetings devoted entirely to the subject. We now see the setting up of hyperthermia clinics in a few treatment centres around the world. It is opportune to ask if hyperthermia should now join surgery, radiotherapy and chemotherapy as a treatment modality of proven usefulness?
Hippocrates reported the use of a hot iron to treat cancer in man, but the earliest clinical report in recent years was that of Busch (1866), who noted that a facial sarcoma completely regressed after two attacks of erysipelas associated with high fever. This led Coley (1893) deliberately to infect patients with erysipelas to achieve the same result and subsequently to prepare his toxin. It still remains uncertain whether the favourable results seen were due to the induced hyperthermia or other induced host responses. Westermark (1898) treated carcinoma of the cervix with hot douches, whilst Warren (1935) introduced whole body heating with radiant heat or diathermy. Little further was done until the past decade, since when there has been a great revival of interest. Limited clinical experiment has been backed up by a very considerable laboratory effort to define the mechanisms and optimum conditions for the hyperthermic treatment of cancer.
There are several reasons why this new method could be of interest. The first and most obvious is that the treatment of cancer by other techniques still fails to cure in the majority of patients. Relapse occurs either due to failure of control of local disease or because of metastases. Any new method which could increase either local or systemic control would be of interest, even if it adds only a small increment of success. Both local and systemic hyperthermia have now been clearly documented to produce regressions in patients, who have failed conventional methods.
The current uncertainties largely range around the physical aspects' of inducing the heat and measuring the ensuing temperatures, although the biological responses largely are in favour of successful therapy. The original evidence that malignant cells are more sensitive to heat than normal cells has now been questioned and open to 0141-0768/81/120865-03/$01.00/0 doubt, but there is an increasing body of work to show that nutritionally deprived cells in tumours resulting from outgrowing their vascular supply are more sensitive. These cellsare probably also at a lower pH than normal and this also markedly sensitizes cells to heat. Although hypoxia may not alter thermal sensitivity, it is the hypoxic cells which are most resistant to ionizing radiation and are thought to be the cause of some radiation failures. Also, hyperthermia does not have the same cell mitotic cycle phase dependence as ionizing radiation, so that cells in the synthetic. phase (S-phase) remain sensitive to heat whilst they are relatively resistant to radiation. It can be seen that the two treatment methods might therefore be complementary.
In addition, it has been shown that hyperthermia enhances the response of cells and tissues to X radiation and some cytotoxic drugs. Differences in the circulatory anatomy in tumours from that in normal tissues may result in less, cooling of the former when external sources of heat are applied. The perfusing blood at the lower core temperature of the host will cool the heated normal tissues more rapidly than those with the malignant circulation. This tumour microvasculature also appears to be more sensitive to heat than its normal counterpart and may exhibit much more marked collapse for the same degree of hyperthermia. This will have the double effect of increasing the efficiency of external heating methods even more, and increasing ischaemic necrosis of the tumour.
Various mechanisms have been proposed to explain the cytotoxic effects of hyperthermia. These include direct damage to DNA and RNA and changes in their rates of synthesis and that of associated proteins. Effects on lysosomal membrane 'stability have been proposed as another mechanism of cell killing, whilst increased permeability of the cell membrane has been suggested as the mechanism for the enhancement of the action of the cytotoxic drug, adriamycin. Explanations for the interaction of hyperthermia with ionizing radiation and other cytotoxic drugs, include membrane effects and interference with the repair of sublethal and potentially lethal damage.
The magnitude of the cell killing of heat is proportional to the temperature employed and the time of exposure. Although there is a wide range in the thermal sensitivity of different cells and tissues, as a general working rule, it is necessary to reduce the heating time by a factor of 2 for every 1°C increase in temperature above 42°C in order to maintain an iso-effect. Thus there is a need for an accurate definition of the induced temperatures which should be as uniform as possible.
The heating time is also critical for other reasons. Heat-induced reduction of cytotoxicity from a subsequent heat shock is now well described. This so-called thermal tolerance may be seen during a single heat treatment, as for example following a period of time at 40°C before the main heat treatment at a higher temperature. This could be of practical concern if the method of heating only results in a slow rise of temperature before the desired therapeutic level is reached. Tolerance may also occur to subsequent treatments after the first treatment of the series. The time course of this effect is not well defined in the clinical situation, but extrapolation from animal experiments suggest that it should be of little concern if the individual treatment exposures are separated by more than 96 h.
The sequence and temporal separation of combined hyperthermia treatments with radiation may be of great importance. Although there is hyperthermic potentiation of radiation effects, available data from experimental work suggests similar enhancements for both normal and tumour tissues when the two are given together. However, separation by a few hours, with the radiation first, may result in therapeutic gain as the normal tissue effect appears to recover more rapidly than that seen in experimental tumours. Clinical trials to test this proposal are in progress.
The interaction of hyperthermia with drugs has largely been documented in experimental systems. In the main, most alkylating agents have their action potentiated as do some of the anti-tumour antibodies such as adriamycin and bleomycin. Experimental data on normal tissue tumour responses are few but in this author's experience, may exceed those seen in tumours; whilst clinical data on therapeutic gain are minimal. These effects of hyperthermia either alone or in combination with other treatments have been reviewed more extensively elsewhere (Field & Bleehen 1979) .
A major reason for the current clinical uncertainties relates to problems in the methodology for inducing hyperthermia. Various techniques have been developed, all of which still have major problems associated with them, and the dosimetric precision attainable with radiotherapy is not yet possible. Methods include whole body and localized heating techniques. These are reviewed more extensively elsewhere (Short & Turner 1980 , Har-Kedar & Bleehen 1976 .
Whole body heating may be advantageous because temperature uniformity will be obtained and will also heat both primary and secondary tumours. But it is limited to a maximum of around 41.5-42°C for several hours and affords no thermal protection for normal tissues. In spite of this, several groups have now reported treating a total of approximately 600 patients using a variety of methods. These include radiant heat cabinets boosted with radiofrequency (RF); immersion in a hot wax bath; heated suits or blankets; and extracorporeal heat exchange of perfused blood. The patients so treated have all had advanced malignancies which have failed all conventional therapies. Even so, a tumour response rate of' around 30%, of which about 6% were complete responders, has been reported either for heat alone or in combination with chemotherapy. Unfortunately most of these responses have only been of short duration. Patient toxicity, although not absent, has usually been acceptable.
Regional hyperthermic perfusion, usually of localized tumours in limbs such as sarcomas and melanomas, has been reported by at least 9 groups in around 900 patients. Favourable results have been claimed either for heat alone or in combination with alkylating agents such as phenylalamine mustard. These results, which do look good, are very difficult to assess as they are only matched against historical controls. The diseases selected do have a variable long natural history and only randomized control studies will permit critical assessment.
Intracavitary infusion has been used at several sites. In the bladder, where the greatest experience has been obtained, damage to the normal mucosa has severely limited its usefulness. Data from other sites such as peritoueal lavagefor carcinomatosis peritonei, are too scanty for critical assessment.
The main direction in which clinical hyperthermia is currently directed is to an assessment of the value of the local heating to restricted tumour volumes. This is effected by deposition of energy using electromagnetic waves (RF, microwaves) or ultrasound of appropriate frequencies. However, none of the techniques currently available can produce satisfactory thermal distributions at depth in either the thorax or abdomen. The depths of penetration of microwaves (300-2450 MHz) and RF (0.5--30 MHz) depend on the frequency selected and absorbing capacities of tissues such as fat. Uniform ultrasound distribution is limited by soft tissue/bone and tissue/gas interfaces. Depth dose problems may be partially overcome by phased arrays of microwave applicators or focused ultrasound. These latter techniques are only just commencing trial in the clinic and detailed reports are awaited. At present, virtually all clinical data relate to metastatic tumours in skin and superficial lymph nodes, together with some head and neck cancers. Regression of such lesions and some longterm control has been reported from a few centres where advanced tumours which have failed conventional methods have been treated. No particular tumour specificities have been demonstrated. However impressive these data are, they must still largely be regarded as Phase I studies demonstrating the possibility of an effect, rather than confirmation of the proven clinical usefulness of hyperthermia. This will need to await more formal controlled studies once better heating methods are available.
The difficulties in producing uniform tumour heating are matched by problems with temperature measurement. At present, all practical methods are invasive even though thermocouples of considerably less than I mm diameter are available. These may interact with electromagnetic waves and result in spurious temperature records, excessive local heating, or at the least disturbance of the local vascular anatomy. Non-interactive temperature detectors, with dielectric constants similar to those of tissue, are being developed and should overcome some of the problems. Noninvasive thermometry methods of practical value are still some way off, although theoretically possible.
Whilst hyperthermia should be seriously considered as an additional treatment modality for cancer all the clinical results so far indicate promise rather than fulfilment of this belief. Results are all preliminary and often anecdotal, not because of errors in the biological premise but due to inadequacies in the physical techniques. Until these latter problems are overcome and the clinical biology adequately investigated, such treatments should be carried out in a limited number of departments capable of making a balanced scientific assessment of their potential. Indiscriminate optimism is likely to be as dangerous as ignorant scepticism.
Norman Sense about wisdoms?' Mr Bowdler Henry in the 1930s drew attention to the often severe problems created by impacted lower third molar teeth (Henry 1934 (Henry , 1935 . He estimated that half the population would require the removal of these teeth before the age of 30 (Henry & Morant 1936) . Since that time, there have been further attempts to estimate the prevalence of impacted third molar teeth (Bjork et al. 1956 , Dachi & Howell 1961 , Morris & Jerman 1971 . Probably the best study is that of Aitasalo . et al. (1972) who, on the basis of examining the radiographs of 4063 patients attending for general dental treatment at the University Institute of Dentistry, Turku, found the prevalence in the 20-29 age group to be 27%. Although all impacted third molar teeth will not come to treatment, they still represent a formidable problem in health care. There is evidence that the removal of a lower premolar tooth results in a lowered incidence of third molar impactions and that the removal of a lower molar virtually eliminates third molar impactions (Cryer 1967 , Faubion 1968 , Plint 1970 , 'Richardson 1975 , Rindler 1977 , Lawlor 1978 .
The increasing success of caries prevention in children and adolescents must result in fewer extractions for other than orthodontic reasons and, therefore, in a greater incidence of impacted third molars. 1Based on paper read to Section of Odontology, 18 May 1981
